Skip to main content
. 2021 Sep 21;97(12):597–599. doi: 10.1212/WNL.0000000000012588

Figure 2. Florbetapir Status by Diagnosis.

Figure 2

(A) Florbetapir distribution of participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) who are cognitively normal (N) or have subjective memory complaints (SMC), early mild cognitive impairment (EMCI), or late mild cognitive impairment (LMCI). (B) Flortaucipir (FTP) positivity according to amyloid status (β-amyloid [Aβ]+ or Aβ−) consistent with clinical diagnosis across Braak stage 1, Braak 3 and 4, and Braak 5 and 6. AD = Alzheimer disease; MCI = mild cognitive impairment; PVC = partial volume correction; SUVR = standardized uptake value ratio.